Research

Hormonal

Loss of GIP receptor (GIPR) signaling specifically in GABAergic neurons enhances the body weight loss efficacy of GLP-1 receptor agonists (such as semaglutide or tirzepatide) and dual incretin agonists.

Current obesity medications that target both GLP-1 and GIP receptors (like tirzepatide) work partly by engaging specific brain neurons (GABAergic neurons expressing GIPR). Research suggests that the body's natural GIP signaling in these neurons might actually limit how much weight you can lose with GLP-1 drugs alone. This implies that future treatments might be optimized by either stimulating or blocking GIP signaling in these specific brain cells to maximize weight loss while managing side effects like nausea.

GoodSupportsHIGH confidence
GIPR in GABAergic neurons is essential for the enhanced weight loss efficacy of dual incretin agonism, yet, surprisingly, its removal enhances the effect of GLP-1R agonism alone.
Jordan Wean et al. · Molecular Metabolism · 2024

Why this rating

High-quality preclinical evidence using genetically modified mouse models (GIPR knockout) with clear phenotypic outcomes, though translational to humans requires caution due to species differences in drug affinity.

Source

Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss

Jordan Wean et al. · Molecular Metabolism · 2024

DOI 10.1016/j.molmet.2024.102074

mechanism_onlyCited 20×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →